National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 48229-48230 [2021-18501]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 164 / Friday, August 27, 2021 / Notices
48229
Appendix I: Statutory Requirement of Annual Report Components
As amended by the above laws, the Social Security Act (the Act}-specl/lcal/y section 1890{b)(S){A)mandates that the entity report to Congress and the Secretary of the Department of Health and Human
services (HHS) no later than March 1st of each year.
The report must Include descriptions of:
•
•
•
•
•
•
how NQF has Implemented quality. and efficiency measurement Initiatives under the Act and
coordinated these Initiatives with those Implemented by other payers;
NQF's recommendations with respect to an Integrated national strategy and priorities for
healthcare performance measurement In all applicable settings;
NQF's performance of the duties required under Its contract with HHS (Appendix A}:
gaps In endorsed quallty and efficiency measures, Including measures that are within priority
areas Identified by the Secretary. under HHS' national strategy, and where quality and efficiency
measures are unavailable or Inadequate to Identify or address such gaps;
areas In which evidence Is lnsu/ftclent to support endorsement of measures In priority areas
Identified by the National auallty Strategy, and where targeted research may address such gaps;
matters related to convening multlstakeholder groups to provide Input on: a) the selection of
certain quality and efficiency measures, and b) national priorities fr,r Improvement In population
health and In the delivery of healthcare services fr,t conslderl:Jtlon under the National Quality
Strategy;.(Throughout This Report, the Relevant Statutory Language Appears In ltallc/1ed Text.,
n.d.)
an lteml1atlon off/npncial tnfr,rmotlon fer the /lscol year ending September 30 of the preceding
year, fnc/µdlng: (I) onnua/ revenues of the entity (Including ony government funding, private
sector contributions, grontS, membership revenues, ond Investment revenue); {II) annuol
expenses of the entity (lnc/ud/ng.grantS paid, benefits paid, salaries or other compensotlon,
fundralslng expenses, ond overhead casts}; and (Ill) a breakdown of the amount awarded per
contracted task order and the specific projects funded In each task order assigned to the entity;
and
• any updates or modifications of Internal po/le/es and procedures of the entity as they relate to
the duties of the entity under this section, Including: {I) speclflcal/y Identifying any modifications
to the disclosure of Interests and conflicts of Interests fr,r committees, work groups, task fetces,
and advisory panels of the entity; and (II) lnfr,tmatlon on external stakeholder participation In
the duties of the entity under this.section (Including complete rosters fer all committees, work
groups, tosk forces, and advisory panels funded through government contracts, descriptions of
relevant Interests and any conflicts of Interest fer members.of al/committees, work groups, task
fr,rces, and advisory panels, and the total percentage by health care sector of all convened
committees, work groups, task ferces, and advisory panels,
[FR Doc. 2021–18485 Filed 8–26–21; 8:45 am]
BILLING CODE 4150–28–C
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
lotter on DSK11XQN23PROD with NOTICES1
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Sep<11>2014
17:52 Aug 26, 2021
Jkt 253001
PO 00000
Frm 00116
Fmt 4703
Sfmt 4703
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
E:\FR\FM\27AUN1.SGM
27AUN1
EN27AU21.084</GPH>
•
48230
Federal Register / Vol. 86, No. 164 / Friday, August 27, 2021 / Notices
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Implementation Cooperative Agreement (U01
Clinical Trial Required); Investigator Initiated
Extended Clinical Trial (R01 Clinical Trial
Required).
Date: September 27, 2021.
Time: 11:45 a.m. to 3:45 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G56,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Poonam Tewary, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G56, Rockville, MD
20852, (301) 761–7219, tewaryp@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: August 23, 2021.
Tyeshia Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–18501 Filed 8–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: August 23, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Center for Advancing
Translational Sciences; Notice of
Closed Meetings
[FR Doc. 2021–18505 Filed 8–26–21; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the
cooperative agreement applications, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; RFA–TR–21–009: Screening
for Conditions by Electronic Nose
Technology (SCENT).
VerDate Sep<11>2014
17:52 Aug 26, 2021
Jkt 253001
Date: September 28, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1078, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Rahat (Rani) Khan, Ph.D.,
Scientific Review Officer, Office of Grants
Management and Scientific Review, National
Center for Advancing Translational Sciences,
National Institutes of Health, 6701
Democracy Boulevard, Room 1078, Bethesda,
MD 20892, 301–894–7319, khanr2@
csr.nih.gov.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; National Center for
Advancing Translational Sciences Special
Emphasis Panel.
Date: September 30, 2021
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1078, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Alumit Ishai, Ph.D.,
Scientific Review Officer, Office of Grants
Management and Scientific Review, National
Center for Advancing Translational Sciences,
National Institutes of Health, 6701
Democracy Boulevard, Suite 1000, Bethesda,
MD 20892, 301–827–5819, alumit.ishai@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
PO 00000
Frm 00117
Fmt 4703
Sfmt 9990
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Neurological Sciences
Training Initial Review Group; NST–1 Study
Section.
Date: September 20–21, 2021.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Virtual
Meeting).
Contact Person: William C. Benzing, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
NINDS, NIH, NSC, 6001 Executive Blvd.,
Suite 3204, MSC 9529, Bethesda, MD 20892–
9529, (301) 496–0660, benzingw@
mail.nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; NIH BRAIN Initiative
Advanced Postdoctoral Career Transition
Award to Promote Diversity (K99/R00).
Date: September 23, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Virtual
Meeting).
Contact Person: Lataisia Cherie Jones,
Ph.D., Scientific Review Officer, NINDS,
Scientific Review Branch, 6001 Executive
Blvd., Suite 3208, Rockville, MD 20852, 301–
496–9223, lataisia.jones@nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; HEAL Initiative: Pain
Therapeutics Development [Small Molecules
and Biologics].
Date: September 27, 2021.
Time: 10:00 a.m. to 3:00 p.m..
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Virtual
Meeting).
Contact Person: Shanta Rajaram, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH, NSC, 6001 Executive Blvd.,
Suite 3208, MSC 9529, Bethesda, MD 20892,
(301) 435–6033, rajarams@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: August 23, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–18508 Filed 8–26–21; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\27AUN1.SGM
27AUN1
]]>Agencies
[Federal Register Volume 86, Number 164 (Friday, August 27, 2021)]
[Notices]
[Pages 48229-48230]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-18501]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning
[[Page 48230]]
individuals associated with the grant applications, the disclosure of
which would constitute a clearly unwarranted invasion of personal
privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation
Cooperative Agreement (U01 Clinical Trial Required); Investigator
Initiated Extended Clinical Trial (R01 Clinical Trial Required).
Date: September 27, 2021.
Time: 11:45 a.m. to 3:45 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G56,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Poonam Tewary, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room 3G56, Rockville, MD
20852, (301) 761-7219, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: August 23, 2021.
Tyeshia Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-18501 Filed 8-26-21; 8:45 am]
BILLING CODE 4140-01-P
